Ensysce Biosciences Expands Global Opioid Patent Portfolio
Rhea-AI Summary
Ensysce Biosciences (NASDAQ:ENSC) announced on January 21, 2026 that the Brazilian Patent Office issued a Notice of Allowance for a patent (PI0919711-7) covering additional opioid families that use the company's proprietary TAAP™ (Trypsin Activated Abuse Protection) and MPAR® (Multi-Pill Abuse Resistance) technologies.
The allowed patent includes both composition of matter and method of use claims, and the company says this expands its global intellectual property protection for next-generation analgesics, complementing existing allowances in North America, the EU, and South America. Management framed the development as strengthening its pain portfolio and advancing safer opioid formulations without compromising pain relief.
Positive
- Brazil patent allowance granted on Jan 21, 2026 (PI0919711-7)
- Claims include composition of matter and method of use
- Expanded global IP footprint including North America, EU, South America
- TAAP and MPAR applied across additional opioid families
Negative
- None.
News Market Reaction – ENSC
On the day this news was published, ENSC declined 2.23%, reflecting a moderate negative market reaction. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $71K from the company's valuation, bringing the market cap to $3M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
ENSC gained 11.53% while key biotech peers like PLRZ, SILO, TTNP, and NCNA declined between ~2–4%, indicating a stock-specific move driven by the Brazilian patent allowance.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 08 | EU ADHD patent | Positive | -0.9% | EU Notice of Allowance for PF8026 ADHD abuse-protected prodrug patent. |
| Jan 05 | Shareholder letter | Positive | +10.6% | Annual letter detailing clinical progress, financing and new MPAR patent. |
| Dec 09 | Phase 3 initiation | Positive | -11.3% | First patient enrolled in pivotal Phase 3 PF614 pain trial. |
| Dec 02 | US MPAR patent | Positive | -4.6% | U.S. Notice of Allowance extending MPAR® overdose protection IP to 2042. |
| Nov 20 | FDA feedback | Positive | -12.0% | FDA agreement on PF614 manufacturing approach and path to commercial production. |
ENSC often showed divergence, with shares frequently declining on positive clinical and IP milestones, and only one recent event aligning with upbeat news.
Over the past few months, Ensysce reported several positive milestones, including FDA manufacturing alignment for PF614 on Nov 20, 2025, broader MPAR® patent protection through 2042, and initiation of the pivotal PF614 Phase 3 trial on Dec 9, 2025. It also secured EU patent protection for ADHD therapy PF8026 and outlined financing progress in its 2025 shareholder letter. Despite these constructive updates, shares often moved lower afterward. Today’s Brazilian patent allowance further extends global IP around TAAP™ and MPAR®-based opioids, continuing this IP-expansion trajectory.
Market Pulse Summary
This announcement expands Ensysce’s global patent estate, adding Brazilian protection for additional opioid families using its TAAP™ and MPAR® platforms. The patent includes composition-of-matter and method-of-use claims, complementing earlier U.S. and EU allowances for pain and ADHD programs. Investors may track how this growing IP base supports PF614’s pivotal development, future partnering interest, and the broader rollout of next-generation analgesics aimed at reducing abuse and overdose risk.
Key Terms
notice of allowance regulatory
composition of matter regulatory
method of use claims regulatory
intellectual property regulatory
opioid use disorder medical
AI-generated analysis. Not financial advice.
~ TAAP™ and MPAR® technologies extended across opioid products to advance safer pain treatment ~
SAN DIEGO, CALIFORNIA / ACCESS Newswire / January 21, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for novel therapeutics while reducing the potential for abuse and overdose, today announced it received a Notice of Allowance from the Brazilian Patent Office for the issuance of a patent* covering additional opioid families, utilizing the Company's proprietary TAAP™ (Trypsin Activated Abuse Protection) and MPAR® (Multi-Pill Abuse Resistance) technologies.
The newly allowed patent includes both composition of matter and method of use claims, further strengthening Ensysce's intellectual property estate and expanding its global protection for Next Generation analgesics. This patent builds on the protection Ensysce has around additional opioid families not only in North America but also in the EU and South America.
"Applying MPAR® technology across all TAAP-designed opioids has the potential to significantly reduce abuse and, importantly, help prevent overdose," said Dr. William Schmidt, Chief Medical Officer of Ensysce Biosciences. "This represents a meaningful advancement in patient safety without compromising pain relief."
"We continue to expand our intellectual property footprint to support the global development of safer, more effective therapies," said Dr. Lynn Kirkpatrick, CEO of Ensysce Biosciences. "This patent strengthens our pain portfolio program and underscores the transformative potential of our TAAP™ and MPAR® platforms. Together with our recently announced patent allowance covering ADHD and opioid use disorder products, this progress moves us closer to a future in which patients can be treated effectively without the devastating consequences of misuse or overdose."
* 'Pharmaceutical Compositions with Attenuated Release of Phenolic Opioids' Brazil Patent No. PI0919711-7
About Ensysce Biosciences
Ensysce Biosciences is a clinical stage company with a goal of disrupting the analgesic landscape by introducing a new class of highly novel opioids for the treatment of severe pain. Leveraging its Trypsin-Activated Abuse Protection (TAAPTM) and Multi-Pill Abuse Resistance (MPAR®) platforms, the Company is developing unique, tamper-proof treatment options for pain that minimize the risk of both drug abuse and overdose. Ensysce's products are anticipated to provide safer options to treat patients suffering from severe pain and assist in preventing deaths caused by medication abuse. For more information, please visit www.ensysce.com.
Forward-Looking Statements
Statements contained in this press release that are not purely historical may be deemed to be forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. Without limiting the foregoing, the use of words such as "may," "intends," "can," "might," "will," "expect," "plan," "possible," "believe" and other similar expressions are intended to identify forward-looking statements. The product candidates discussed are in clinic and not approved and there can be no assurance that the clinical programs will be successful in demonstrating safety and/or efficacy, that Ensysce will not encounter problems or delays in clinical development, or that any product candidate will ever receive regulatory approval or be successfully commercialized. All forward-looking statements are based on estimates and assumptions by Ensysce's management that, although Ensysce believes to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Ensysce expected. In addition, Ensysce's business is subject to additional risks and uncertainties, including among others, the initiation and conduct of preclinical studies and clinical trials; the timing and availability of data from preclinical studies and clinical trials; expectations for regulatory submissions and approvals; potential safety concerns related to, or efficacy of, Ensysce's product candidates; the availability or commercial potential of product candidates; the ability of Ensysce to fund its continued operations, including its planned clinical trials; the dilutive effect of stock issuances from our fundraising; and Ensysce's and its partners' ability to perform under their license, collaboration and manufacturing arrangements. These statements are also subject to a number of material risks and uncertainties that are described in Ensysce's most recent quarterly report on Form 10-Q and current reports on Form 8-K, which are available, free of charge, at the SEC's website at www.sec.gov. Any forward-looking statement speaks only as of the date on which it was made. Ensysce undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required under applicable law.
Ensysce Biosciences Company Contact:
Lynn Kirkpatrick, Ph.D.
Chief Executive Officer
(858) 263-4196
Ensysce Biosciences Investor Relations Contact:
Shannon Devine
MZ North America
Main: 203-741-8811
ENSC@mzgroup.us
SOURCE: Ensysce Biosciences Inc.
View the original press release on ACCESS Newswire
FAQ
What did Ensysce (ENSC) announce on January 21, 2026 regarding patents?
What is the scope of the Brazil patent PI0919711-7 for ENSC?
How does the Brazil patent affect Ensysce's global protection for ENSC technologies?
Does the January 21, 2026 patent allow Ensysce (ENSC) to commercialize new opioid drugs immediately?
Which Ensysce technologies are covered by the newly allowed Brazil patent (ENSC)?
What is the patent number announced by Ensysce (ENSC) on January 21, 2026?
